The Genome Editing/Genome Engineering Market Size is valued at 5900.0 Million in 2022 and is predicted to reach 28469.3 Million by the year 2031 at a 19.20 % CAGR during the forecast period for 2023-2031.
Genome engineering is the technique that involves gene modification by certain process include DNA is insertion, cutting, modification or replacement of genome of a living organism. Due to increasing the research and development spend by companies and organization fueling the highest growth of genome engineering market.
Advancement in genomic technologies helping research organizations to take deep dive in genome engineering hence companies are making significant investment in Research and development. For instance, Thermo Fisher Scientific is developing cutting edge CRISPR technology for providing better efficiency and accuracy in research, and to fulfil the unmet demands in research and therapeutics. Additionally, contribution by the research organization and universities are tremendous creating high impact in the market. For instance, in November 2015, a new CRISPR technology was developed by scientists at the University of Massachusetts Medical School. This technology help in the genome editing at specific target location.
Market Segmentation
The Global Genome Editing/Genome Engineering market is segmented on the basis of base technology, product, application, end users and region. Based on the base type, the market is divided into CRISPR, TALEN, ZFN, antisense and other technologies. On the basis of product, the market is segmented into reagents & consumables, software & systems and services. Based on the application, the market is divided into animal genetic engineering, plant genetic engineering, diagnostic applications, drug discovery & development and other. Based on the end users, the market is divided into pharmaceutical companies, biotechnology companies, academic & government and research institutes. Based on region, the market is studied across North America, Asia-Pacific, Europe, and LAMEA. Among that Europe held the largest share of the market, followed by America and Asia Pacific. On the other hand, North America is expected to dominate the market during the analysis of forecast period.
Competitive Landscape
Some of The Key Players in The Genome Editing/Genome Engineering Market:
- Thermo Fisher Scientific Inc.
- Merck & Co. Inc
- Horizon Discovery group plc
- Genscript biotech corporation
- Sangamo Therapeutics Inc.
- lonza group ltd
- Editas Medicine Inc
- Crispr Therapeutics
- Eurofins Scientific Inc
- Precision Biosciences Inc
- Oxford Genetics Ltd.
- Intellia Therapeutics Inc
- Synthego corporation
- Vigene Biosciences Inc
- Epigenie
- Integrated DNA Technologies Inc
- New England Biolabs Inc
- Origene Technologies Inc
- Transposagen Biopharmaceuticals Inc
- Creative Biogene Inc.
- Other Prominent Players
The Genome Editing/Genome Engineering Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2022 |
USD 5900.0 Million |
|
Revenue Forecast In 2031 |
USD 28469.3 Million |
|
Growth Rate CAGR |
CAGR of 19.20 % from 2023 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Technology, By Products, By Application, By End Users |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
Thermo Fisher Scientific Inc., Merck & Co. Inc, Horizon Discovery group plc, Genscript biotech corporation, Sangamo Therapeutics Inc., lonza group ltd, Editas Medicine Inc, Crispr Therapeutics, Eurofins Scientific Inc, Precision Biosciences Inc, Oxford Genetics Ltd., Intellia Therapeutics Inc, Synthego corporation, Vigene Biosciences Inc, Epigenie, Integrated DNA Technologies Inc, New England Biolabs Inc, Origene Technologies Inc, Transposagen Biopharmaceuticals Inc, and Creative Biogene Inc. among others |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
